Cite
HARVARD Citation
Kappelman, M. et al. (2023). Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. American journal of gastroenterology. pp. 674-684. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kappelman, M. et al. (2023). Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. American journal of gastroenterology. pp. 674-684. [Online].